Ozempic, Wegovy Dosing Errors Surge to Poison Control

Poison control centers experienced a substantial rise in calls concerning semaglutide, the active ingredient in Ozempic and Wegovy, following the drug's approval for weight management. Researchers have identified accidental dosing mistakes as the primary driver of this increase, rather than intentional misuse of the medication. A study published in the Journal of the American Medical Association (JAMA) indicated a sharp uptick in calls, with a notable percentage linked to patients taking more than the prescribed weekly dose or increasing their dose too rapidly.

The data suggests that many of these incidents could be preventable with clearer patient education. The study's authors emphasized the importance of reinforcing proper weekly dosing schedules and the necessity of gradual dose escalation under medical supervision. This educational component is crucial for ensuring patient safety and mitigating the risks associated with these potent medications. The increase in calls highlights a potential gap in patient understanding or adherence to prescribed regimens.

While the exact number of calls varies by reporting period, the trend indicates a direct correlation between the drug's wider availability for weight loss and the subsequent rise in accidental overdoses or improper administration. The researchers noted that while the calls did not always result in severe adverse events, they represented a significant burden on poison control resources and posed potential health risks to individuals. The findings underscore the need for ongoing vigilance and proactive communication from healthcare providers to patients initiating treatment with semaglutide-based medications.